

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of: BEAUDOIN, Adrien

Atty. Docket No.: JG/13694.4

Serial No.: N/A

Group Art Unit: To be assigned

Filed: N/A

Examiner: To be assigned

Title: METHODS FOR SCREENING FOR A COMPOUND USEFUL IN THE
TREATMENT OR PREVENTION OF LYMPHOCYTIC DISORDERS,
FOR INHIBITING LYMPHOCYTE ACTIVITY AND PREVENTING OR
TREATING LYMPHOCYTIC DISORDERS

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97

Commissioner for Patents
Alexandria VA 22313-1450

Sir:

Submitted herewith on a PTO-1449 form is a listing of the documents known to applicant in order to comply with applicant's duty of disclosure pursuant to 37 C.F.R. § 1.56. Copies of the listed documents are also being submitted herewith to comply with the provisions of 37 C.F.R. § 1.98.

The documents listed on the attached PTO-1449 were all cited in the International Search Report of the corresponding PCT Application, a copy of the International Search Report being annexed to the present Information Disclosure Statement.

The submission of any document which is not a statutory bar is not intended as an admission that such document constitutes prior art against the claims of the present application. Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie prior art reference against the claims of the present application.


Statement of Relevancy

10/511133
0104 Rec'd PCT/PTO 1 4 OCT 2004

The listed document is being submitted either in compliance with 37 C.F.R. §1.97(b), within three (3) months of the filing date of a national application or of the date of entry of the national stage in an international application.

Respectfully submitted,

Date: October 6, 2004



Julie Gauvreau
Registration No. 52,532

GOUDREAU GAGE DUBUC
Stock Exchange Tower
Suite 3400, P.O. Box 242
800 Place-Victoria
Montreal, Quebec, Canada
H4Z 1E9
Tel.: (514) 397-4374

Form PTO-1449 (Rev. 7-80)	U.S. Department of Commerce Patent & Trademark Office	ATTY. DOCKET NO. JG/13694.4	SERIAL NO. 10/511133 N/A
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT BEAUDOIN, Adrien et al	
		FILING DATE N/A	GROUP N/A

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		Document number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AL	WO 02071062	09-2002	PCT/Application				
	AM	2,311,084	12-2001	Canada				
	AN							
	AO							
	AP							

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

		MIZUMOTO NORIKATSU et al: "CD39 is the dominant Langerhans cell-associated ecto-NTPDase: Modulatory roles in inflammation and immune responsiveness." Nature Medicine, vol.8, no.4, April 2002, pages 358-365, Xp002251343, April, 2002, ISSN: 1078-8956. p.360. left-hand column, 1. 3-5 and "discussion" section & Nature Medicine, 'online! Retrieved from internet: URL:http://www.nature.com/dynasearch/app/Dynasearch.taf? action=search&sp-n=1&sp-k=&search_fulltext=&sp-pAny&sp-w=Exact&search_volume=8&search_startPage=358 'retrieved on 2003-08-14'
	AR	
		Grandstein R.D.: "Theskinny on CD39 in immunity and inflammation" Nature Medicine, vol.8, no.4, April 2002, pages 336-338, XP002251344, the whole document
	AS	
		Gendron Fernand-Pierre et al: "Novel inhibitors of nucleoside triphosphate diphosphohydrolases: Chemical synthesis and biochemical and pharmacological characterizations." Journal of Medicinal Chemistry, vol.43, no.11, 1 June 2000, pages 2239-2247, XP002251346, ISSN: 0022-2623, the whole

Best Available Copy

0704 17-03 10/07/00 1 4 OCT 2004

	document	10/511133
AT		

Examiner	Date considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

US Comm-DC 80-3985

Best Available Copy